OPSENS ANNOUNCES UPSIZE TO AND PROVIDES ADDITIONAL DETAILS REGARDING ITS PROPOSED EQUITY FINANCING
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
OPSENS INC. ANNOUNCES UPSIZE TO AND provides additional details regarding its proposed equity financing
Quebec City, Quebec, November 23, 2016 – Opsens Inc. (“Opsens” or the “Corporation”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that it has amended the terms of its previously announced marketed offering (the “Offering”) of common shares (the “Shares”) to increase the size of the Offering to approximately $13,000,500. The Corporation will file an amended and restated preliminary short form prospectus to reflect this upsize and provide additional details concerning the Offering. The Corporation will offer up to 8,667,000 Shares at a price of $1.50 per Share for maximum gross proceeds of approximately $13,000,500. The Offering will be conducted on a best effort basis through Paradigm Capital Inc. (“Paradigm”), acting as lead agent, and including RBC Capital Markets and M Partners Inc. (collectively with Paradigm, the “Agents”).
The Corporation has agreed to grant the Agents an option to cover over-allotments and for market stabilization purposes (the “Over-Allotment Option”), which will allow the Agents to arrange for purchasers to acquire up to an additional 1,300,000 Shares sold under the Offering. The Over-Allotment Option will be exercisable, in whole or in part, at any time up to 30 days after the closing of the Offering.
The Offering is being made pursuant to a short form prospectus filed in each of the provinces of Quebec, Ontario, Alberta and British Columbia. A copy of the amended and restated preliminary short form prospectus will be available on SEDAR at www.sedar.com.
The Offering is expected to close on or about December 8, 2016 and is subject to certain customary conditions and regulatory approvals, including the approval of the TSX Venture Exchange and the entering into by the Corporation and the Agents of an agency agreement.
This press release does not constitute an offer of securities for sale in the United States or to “U.S. persons” (“U.S. persons”), as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities being offered have not been, nor will be, registered under the U.S. Securities Act or any state securities laws, and may not be offered or sold in the United States or to U.S. persons absent registration or an applicable exemption from such registration requirements.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Corporation develops, manufactures and installs innovative fibre optic sensing solutions for critical applications, such as the monitoring of oil wells and other demanding industrial applications.
Except for historical information, this press release may contain “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws that reflect Opsens’ current expectation regarding future events, including, without limitation the timing and completion of the Offering. Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements. Opsens expressly disclaims any intention to update or revise any forward-looking statements and information whether as a result of new information, future events or otherwise, other than as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Thierry Dumas, CPA, CA, Chief Financial Officer, 418.781-0333
Louis Laflamme, CPA, CA, President and Chief Executive Officer, 418.781-0333